Research ArticleClinical Studies
Efficacy of Irinotecan as Third-line Chemotherapy for Unresectable or Recurrent Gastric Cancer
MINORU FUKUCHI, KOHKI KUWABARA, TORU ISHIGURO, YOUICHI KUMAGAI, KEIICHIRO ISHIBASHI, ERITO MOCHIKI and HIDEYUKI ISHIDA
In Vivo March 2020, 34 (2) 903-908; DOI: https://doi.org/10.21873/invivo.11856
MINORU FUKUCHI
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
KOHKI KUWABARA
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
TORU ISHIGURO
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
YOUICHI KUMAGAI
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
KEIICHIRO ISHIBASHI
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
ERITO MOCHIKI
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
HIDEYUKI ISHIDA
Department of Digestive Tract and General Surgery, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
In this issue
In Vivo
Vol. 34, Issue 2
March-April 2020
Efficacy of Irinotecan as Third-line Chemotherapy for Unresectable or Recurrent Gastric Cancer
MINORU FUKUCHI, KOHKI KUWABARA, TORU ISHIGURO, YOUICHI KUMAGAI, KEIICHIRO ISHIBASHI, ERITO MOCHIKI, HIDEYUKI ISHIDA
In Vivo Mar 2020, 34 (2) 903-908; DOI: 10.21873/invivo.11856
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.